Gonaki

Alchornea cordifolia contains polyphenols (gallic acid, ellagic acid, quercetin), alkaloids (yohimbine, alchorneine), saponins, and fatty acid methyl esters that exert antioxidant effects via DPPH radical scavenging and antimicrobial action through membrane disruption at low minimum inhibitory concentrations. In animal and in vitro models, aqueous leaf and fruit extracts demonstrated hepatoprotective activity reducing elevated ALT and AST by more than 40–45% at doses of 200–800 mg/kg, and antimalarial efficacy against Plasmodium falciparum 3D7 with an IC50 of 4.9 µg/mL and a selectivity index exceeding 69.4.

Origin & History

Alchornea cordifolia is a tropical shrub or small tree native to sub-Saharan Africa, distributed widely across West, Central, and East Africa, including Nigeria, Cameroon, Senegal, and the Democratic Republic of Congo. It thrives in humid forest margins, riverbanks, and disturbed secondary forest ecosystems, tolerating a range of soil types from alluvial lowlands to lateritic uplands. Traditionally cultivated and wildcrafted, the plant is rarely the subject of formal agricultural cultivation and is predominantly harvested from wild populations for local medicinal use.

Historical & Cultural Context

Alchornea cordifolia has been a cornerstone of traditional medicine across sub-Saharan Africa for centuries, employed by healers in Nigeria, Ghana, Cameroon, Senegal, the Democratic Republic of Congo, and neighboring countries to treat a wide spectrum of ailments including malaria, skin infections, sexually transmitted infections, rheumatic pain, diabetes, and liver disorders. The plant holds cultural significance in many communities as a 'polychrest' remedy — a single botanical addressing multiple disease states — and its leaves, roots, bark, and fruits are each assigned distinct therapeutic roles depending on regional ethnobotanical tradition. Preparation methods vary by intended use: leaf decoctions are consumed for systemic conditions such as fever and liver complaints, while leaf poultices or infusion washes are applied directly to the skin for dermatitis, wounds, and fungal infections. The plant is referenced in multiple African pharmacopeial compendiums and ethnobotanical surveys documenting its sustained importance in primary healthcare settings where access to pharmaceutical medicines remains limited.

Health Benefits

- **Antioxidant Activity**: Methanolic and infusion leaf extracts exhibit total phenolic content of 120.38–213.12 mg GAE/g and total flavonoid content of 9.66–57.18 mg RE/g, with DPPH radical scavenging capacity that increases concentration-dependently from 50 to 250 µg/mL, attributed to gallic acid, ellagic acid, quercetin, rutin, myricetin, and kaempferol.
- **Antimicrobial Properties**: Saponins, tannins, and alkaloids in leaf extracts disrupt microbial cell membranes, producing low minimum inhibitory concentrations against Escherichia coli (ATCC 28923) and Bacillus subtilis (ATCC 6051), supporting traditional use in treating infectious skin conditions and wounds.
- **Hepatoprotective Effects**: Aqueous extracts at 200–800 mg/kg significantly reduced isoniazid- and rifampicin-induced elevations in serum alanine aminotransferase and aspartate aminotransferase by more than 40–45% in rabbit models, suggesting cytoprotective activity mediated by polyphenolic antioxidants that attenuate oxidative hepatocellular damage.
- **Antimalarial Activity**: Fruit aqueous extracts inhibit Plasmodium falciparum 3D7 growth in vitro with an IC50 of 4.9 µg/mL and a selectivity index greater than 69.4, indicating potent antiparasitic activity with a favorable therapeutic window compared to host cell cytotoxicity.
- **Anti-inflammatory and Analgesic Action**: Methyl salicylate, identified at 25.3% of fruit essential oil, provides a mechanistic basis for the plant's traditional analgesic use via cyclooxygenase inhibition, while tannins and flavonoids contribute additional anti-inflammatory activity by quenching reactive oxygen species that drive inflammatory cascades.
- **Antidiabetic and Anti-hyperlipidemic Potential**: Leaf extracts have demonstrated blood glucose and lipid-modulating effects in Wistar rat models, with reductions in serum cholesterol and triglycerides, though specific molecular targets such as alpha-glucosidase or HMG-CoA reductase inhibition remain to be fully characterized in this species.
- **Skin Disease Management**: The combined antibacterial, anti-inflammatory, and antioxidant properties of leaf polyphenols, particularly condensed tannins (0.55–1.94 mg EC/g) and anthocyanins (up to 5.53 mg C3GE/g in mature leaves), support traditional topical use for dermatological conditions including eczema, fungal infections, and inflammatory skin lesions.

How It Works

The antioxidant mechanism of Alchornea cordifolia centers on polyphenols such as gallic acid, ellagic acid, quercetin, rutin, and kaempferol, which donate hydrogen atoms or electrons to stabilize reactive oxygen and nitrogen species, with DPPH scavenging activity increasing proportionally to extract concentration from 50 to 250 µg/mL. Antimicrobial activity is attributed to saponins and tannins disrupting phospholipid bilayer integrity of bacterial cell membranes, leading to cytoplasmic leakage and cell death, while alkaloids such as alchorneine may intercalate with microbial DNA or inhibit nucleic acid synthesis at low inhibitory concentrations. The hepatoprotective effect observed in animal models likely involves polyphenol-mediated suppression of lipid peroxidation and preservation of mitochondrial membrane potential, reducing the oxidative stress cascade triggered by drug-induced reactive metabolites that elevate transaminases. The analgesic and anti-inflammatory actions are mechanistically supported by methyl salicylate in the volatile fraction, a known non-selective cyclooxygenase inhibitor that reduces prostaglandin biosynthesis, complemented by flavonoids that downregulate nuclear factor-kappa B-driven pro-inflammatory cytokine expression.

Scientific Research

The evidence base for Alchornea cordifolia consists exclusively of in vitro assays, ex vivo parasite inhibition studies, and small-scale animal experiments, with no published human clinical trials identified in the available literature. In vitro studies have quantified DPPH scavenging, minimum inhibitory concentrations against standard bacterial strains, and cytotoxic selectivity against hepatocellular carcinoma cell lines, providing mechanistic plausibility but lacking translational confirmation in humans. Animal studies in Wistar rats and rabbit models have measured lipid panel changes and serum transaminase responses at doses of 200–800 mg/kg aqueous extract, reporting statistically significant hepatoprotective outcomes, though interspecies dose extrapolation to humans is unreliable without pharmacokinetic bridging data. The body of research, while consistent in demonstrating bioactivity across multiple assay systems, remains preliminary; rigorous dose-escalation toxicology studies, pharmacokinetic profiling, and Phase I–II clinical trials are entirely absent, substantially limiting confidence in efficacy and safety claims.

Clinical Summary

No human clinical trials have been conducted or published on Alchornea cordifolia for any indication, including skin disease treatment or analgesia. Available evidence derives from in vitro phytochemical and antimicrobial screening, ex vivo Plasmodium falciparum inhibition assays (IC50 4.9 µg/mL, selectivity index >69.4), and animal models demonstrating >40–45% reduction in drug-induced hepatic transaminase elevation at 200–800 mg/kg. While these preclinical findings are biologically coherent with the plant's traditional medicinal applications, effect sizes cannot be translated directly to clinical practice without human pharmacokinetic and efficacy data. Confidence in therapeutic outcomes for human use is currently very low, and all applications remain investigational.

Nutritional Profile

Leaves of Alchornea cordifolia contain quantifiable secondary metabolites rather than significant macronutrient or conventional micronutrient content: saponins (11.5 ± 0.4 mg/100g), steroids (12.0 ± 0.1 mg/100g), tannins including condensed tannins (0.55–1.94 mg EC/g) and total tannins (0.66–1.94 mg EAT/g), alkaloids (9.55 ± 2.0 mg/100g), and glycosides (19.0 ± 1.0 mg/100g). The polyphenol fraction is particularly rich, with total phenolic content of 120.38–213.12 mg GAE/g and total flavonoids of 9.66–57.18 mg RE/g in methanolic extracts, including gallic acid, ellagic acid, quercetin, rutin, myricetin, and kaempferol. Volatile and fatty acid constituents identified by GC-MS include 9-Octadecenoic acid methyl ester (19.93%), 9,12-Octadecadienoic acid methyl ester (18.42%), and Dodecanoic acid 1,2,3-propanetriyl ester (15.87%), while mature leaf anthocyanin content reaches up to 5.53 mg C3GE/g. Bioavailability of these compounds from aqueous decoctions versus organic solvent extracts has not been formally studied in humans; tannin-protein binding may reduce absorption of co-ingested proteins and iron when consumed with meals.

Preparation & Dosage

- **Leaf Decoction (Traditional)**: 10–30 g of dried leaves boiled in 500 mL water for 15–20 minutes, filtered and consumed as a tea 1–3 times daily; the most common preparation across West and Central African ethnomedicine for internal and topical use.
- **Aqueous Extract (Experimental/Animal Studies)**: 200–800 mg/kg body weight used in animal hepatoprotection and antidiabetic models; no validated human equivalent dose has been established and direct extrapolation is not recommended.
- **Methanolic/Ethanol Extract (Research Grade)**: Concentrations of 50–250 µg/mL employed in in vitro DPPH and antimicrobial assays; not formulated for human supplementation.
- **Leaf Infusion (Cold or Hot)**: Fresh or dried leaves steeped in water to prepare topical washes for skin diseases and wound care; applied externally to affected areas 2–3 times daily in traditional practice.
- **Fruit Aqueous Extract (Antimalarial Use)**: Prepared by macerating fresh or dried fruits in water; IC50 of 4.9 µg/mL demonstrated in vitro against P. falciparum but human dosing protocols are undefined.
- **Standardization**: No standardized commercial extract with defined marker compound percentages (e.g., gallic acid, quercetin) is currently available; clinical-grade standardization has not been established.

Synergy & Pairings

Alchornea cordifolia's polyphenol-rich profile may produce additive or synergistic antioxidant effects when combined with other flavonoid-dense botanicals such as Moringa oleifera or Hibiscus sabdariffa, with the complementary radical-scavenging profiles of their respective phenolic acids and anthocyanins potentially broadening free radical quenching across multiple oxidative pathways. The methyl salicylate component of the fruit essential oil may act synergistically with ginger (Zingiber officinale) gingerols, both targeting prostaglandin synthesis through cyclooxygenase modulation, potentially enhancing analgesic and anti-inflammatory outcomes in traditional polyherbal formulations used across West Africa. Co-administration with bioavailability enhancers such as piperine from black pepper has theoretical merit for increasing absorption of quercetin and kaempferol, as demonstrated for structurally similar flavonoids in pharmacokinetic studies, though this specific combination has not been tested with Alchornea cordifolia extracts.

Safety & Interactions

In animal studies, aqueous Alchornea cordifolia extracts at 200–800 mg/kg did not independently elevate serum transaminases and were protective against drug-induced hepatotoxicity, suggesting acceptable acute hepatic safety at experimental doses; however, comprehensive toxicological profiling including subchronic, chronic, mutagenicity, and reproductive toxicity studies has not been published. The high tannin and saponin content of leaf preparations may cause gastrointestinal adverse effects such as nausea, abdominal cramping, and diarrhea at elevated doses, and chronic high-dose tannin ingestion may inhibit intestinal absorption of non-heme iron, zinc, and dietary proteins. No formal drug interaction studies exist; however, the presence of yohimbine-class alkaloids raises theoretical concerns about additive effects with antihypertensive agents, alpha-adrenergic blockers, and monoamine oxidase inhibitors, and the salicylate content of fruit essential oil warrants caution with anticoagulant or antiplatelet therapy. Safety in pregnancy, lactation, pediatric populations, and individuals with hepatic or renal impairment has not been evaluated, and use in these groups cannot be recommended on current evidence.